ReWalk Robotics (NASDAQ:LFWD – Get Free Report) and Nutriband (NASDAQ:NTRB – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk.
Profitability
This table compares ReWalk Robotics and Nutriband’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ReWalk Robotics | -102.03% | -41.89% | -30.83% |
| Nutriband | -315.56% | -71.77% | -56.63% |
Volatility & Risk
ReWalk Robotics has a beta of 2.06, indicating that its stock price is 106% more volatile than the S&P 500. Comparatively, Nutriband has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ReWalk Robotics | 0 | 0 | 1 | 1 | 3.50 |
| Nutriband | 0 | 0 | 0 | 0 | N/A |
ReWalk Robotics presently has a consensus target price of $13.00, suggesting a potential upside of 269.32%. Given ReWalk Robotics’ higher possible upside, equities analysts plainly believe ReWalk Robotics is more favorable than Nutriband.
Institutional and Insider Ownership
26.8% of ReWalk Robotics shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 2.1% of ReWalk Robotics shares are held by insiders. Comparatively, 43.2% of Nutriband shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares ReWalk Robotics and Nutriband’s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ReWalk Robotics | $23.28 million | 1.30 | -$22.13 million | ($3.11) | -1.13 |
| Nutriband | $2.02 million | 29.60 | -$5.49 million | ($0.77) | -7.03 |
Nutriband has lower revenue, but higher earnings than ReWalk Robotics. Nutriband is trading at a lower price-to-earnings ratio than ReWalk Robotics, indicating that it is currently the more affordable of the two stocks.
Summary
ReWalk Robotics beats Nutriband on 10 of the 14 factors compared between the two stocks.
About ReWalk Robotics
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.
About Nutriband
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Receive News & Ratings for ReWalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.
